Zydus Receives Final Approval FromUsfda For Vigabatrin Tablets
Vigabatrin Is Used To Treat One Month To Two-Year-Old Babies With Infantile Spasms. It Is Also Used In Combination With Other Medications To Treat Seizure Disorders.Zydus Received Final Approval From The Usfda To Market Vigabatrin Tablets In The Strength Of 500 Mg. Vigabatrin Tablets Are The Generic Bioequivalent Of The Reference Listed Drug Sabril Tablets. Vigabatrin Is Used To Treat One Month To Two-Year-Old Babies With Infantile Spasms. It Is Also Used In Combination With Other Medications To Treat Seizure Disorders (Epilepsy). Tablets Decreases The Number Of Seizures In Adults And Children Who Have Not Been Able To Control Their Seizures With Other Treatments. It Is An Anticonvulsant Known To Work By Stopping The Breakdown Of A Natural Calming Substance (Gaba) In The Brain. The Drug Will Be Manufactured At The Group
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!